PDAC has the worst outlook of any form of cancer in terms of progression-free and overall survival and is the seventh most common cause of cancer related death worldwide. Around thirty percent of PDAC patients present as locally-advanced[1].
The first-line treatment options in this setting are mainly systemic chemotherapies and is called neoadjuvant treatment.
External beam radiotherapy can be employed for those patients both for no longer responding to chemotherapy or combined with Chemotherapy in the neoadjuvant treatment approach.
ESMO international guidelines actively promote the development of new therapeutic options for this patient group. YntraDose aimed to be placed to become the alternative treatment that is so urgently needed.